Rezera, rebranded from NodThera, filed for an initial public offering to support its decade-long NLRP3-focused work in peripheral artery disease. The company’s IPO queue entry signals renewed interest in inflammasome biology programs that aim to address inflammation-linked vascular disease. The filing indicates that Rezera is seeking additional capital to sustain or expand preclinical-to-clinical progress for NLRP3 modulation. For investors, the key question is whether the company can convert its long-running mechanistic strategy into demonstrable clinical differentiation in PAD. The move also reflects continued capital formation appetite—despite volatile public markets—for companies with clear program longevity and defined therapeutic targets.